Fo-ti (Herb/Suppl)

Brand and Other Names:he shou wu, polygonum multiflorum
  • Print

Suggested Dosing

Check Mfr instruction

raw herb: 9-15 g

Next:

Suggested Uses

Adaptogen, constipation, anti-aging

Previous
Next:

Interactions

Interaction Checker

and Fo-ti

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (0)

                Monitor Closely (0)

                  Minor (44)

                  • acarbose

                    fo-ti increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

                  • amlodipine

                    fo-ti increases effects of amlodipine by pharmacodynamic synergism. Minor/Significance Unknown.

                  • bendroflumethiazide

                    fo-ti increases effects of bendroflumethiazide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).

                  • bumetanide

                    fo-ti increases effects of bumetanide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).

                  • chlorothiazide

                    fo-ti increases effects of chlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).

                  • chlorpropamide

                    fo-ti increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown.

                  • chlorthalidone

                    fo-ti increases effects of chlorthalidone by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).

                  • clevidipine

                    fo-ti increases effects of clevidipine by pharmacodynamic synergism. Minor/Significance Unknown.

                  • cyclopenthiazide

                    fo-ti increases effects of cyclopenthiazide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).

                  • diltiazem

                    fo-ti increases effects of diltiazem by pharmacodynamic synergism. Minor/Significance Unknown.

                  • ethacrynic acid

                    fo-ti increases effects of ethacrynic acid by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).

                  • felodipine

                    fo-ti increases effects of felodipine by pharmacodynamic synergism. Minor/Significance Unknown.

                  • furosemide

                    fo-ti increases effects of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).

                  • glimepiride

                    fo-ti increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.

                  • glipizide

                    fo-ti increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.

                  • glyburide

                    fo-ti increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.

                  • hydrochlorothiazide

                    fo-ti increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).

                  • indapamide

                    fo-ti increases effects of indapamide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).

                  • insulin aspart

                    fo-ti increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

                  • insulin detemir

                    fo-ti increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.

                  • insulin glargine

                    fo-ti increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.

                  • insulin glulisine

                    fo-ti increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.

                  • insulin lispro

                    fo-ti increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.

                  • insulin NPH

                    fo-ti increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown.

                  • insulin regular human

                    fo-ti increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.

                  • isradipine

                    fo-ti increases effects of isradipine by pharmacodynamic synergism. Minor/Significance Unknown.

                  • metformin

                    fo-ti increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown.

                  • methyclothiazide

                    fo-ti increases effects of methyclothiazide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).

                  • metolazone

                    fo-ti increases effects of metolazone by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).

                  • miglitol

                    fo-ti increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown.

                  • nateglinide

                    fo-ti increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown.

                  • nicardipine

                    fo-ti increases effects of nicardipine by pharmacodynamic synergism. Minor/Significance Unknown.

                  • nifedipine

                    fo-ti increases effects of nifedipine by pharmacodynamic synergism. Minor/Significance Unknown.

                  • nisoldipine

                    fo-ti increases effects of nisoldipine by pharmacodynamic synergism. Minor/Significance Unknown.

                  • pioglitazone

                    fo-ti increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown.

                  • repaglinide

                    fo-ti increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown.

                  • rosiglitazone

                    fo-ti increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown.

                  • saxagliptin

                    fo-ti increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown.

                  • sitagliptin

                    fo-ti increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown.

                  • tolazamide

                    fo-ti increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

                  • tolbutamide

                    fo-ti increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown.

                  • torsemide

                    fo-ti increases effects of torsemide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).

                  • verapamil

                    fo-ti increases effects of verapamil by pharmacodynamic synergism. Minor/Significance Unknown.

                  • vildagliptin

                    fo-ti increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown.

                  Previous
                  Next:

                  Adverse Effects

                  Diarrhea

                  Previous
                  Next:

                  Warnings

                  Cautions

                  May cause diarrhea

                  Large doses can cause paresthesia

                  Previous
                  Next:

                  Pregnancy & Lactation

                  Pregnancy Category: N/A

                  Lactation: N/A

                  Pregnancy Categories

                  A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                  B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                  C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                  D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                  X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                  NA: Information not available.

                  Previous
                  Next:

                  Pharmacology

                  Metabolism: N/A

                  Excretion: N/A

                  Mechanism of Action

                  Unknown

                  Previous
                  Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.